

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122791 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01) A61K 45/06 (2006.01)
A61K 31/573 (2006.01) A61K 39/395 (2006.01)
A61K 31/69 (2006.01) A61K 31/454 (2006.01)

(21) International Application Number:

PCT/US2024/058743

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/607,082 06 December 2023 (06.12.2023) US
63/654,907 31 May 2024 (31.05.2024) US

(71) Applicant: **SANOFI-AVENTIS U.S. LLC** [US/US]; 55
Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **CORZO, Kathryn Penkus**; c/o Sanofi, Patent
Department, 450 Water Street, Cambridge, Massachusetts
02141 (US). **OPREA, Ileana Corina**; c/o Sanofi, Patent
Department, 46 avenue de la Grande Armée, 75017 Paris
(FR).

(74) Agent: **ZHOU, Jie** et al.; Morrison & Foerster LLP, 425
Market Street, San Francisco, California 94105 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: USE OF ANTI-CD38 ANTIBODY IN THE TREATMENT OF NEW DIAGNOSED MULTIPLE MYELOMA



(57) Abstract: Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))